Annexon, Inc. filed a current report on August 12, 2026, disclosing second quarter 2026 financial results and an expansion of its vonaprument Phase 3 program in geographic atrophy.

Key Highlights

  • Q2 2026 results disclosed: Annexon announced certain financial results for the second quarter ended June 30, 2026, furnished as Exhibit 99.1.
  • Phase 3 program expansion: The company issued a press release announcing an expansion of the vonaprument Phase 3 program in geographic atrophy.
  • Dual primary endpoint added: A Month 24 dual primary endpoint is being added to complement the existing Month 15 primary endpoint in the Phase 3 program.
  • Open-label extension study: Annexon disclosed plans to launch an open-label extension study as part of the expanded program.
  • Filing signed by CFO: The report was signed by Jennifer Lew, Executive Vice President and Chief Financial Officer, on August 12, 2026.

Annexon Discloses Q2 2026 Results and Vonaprument Program Expansion

Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company headquartered in Brisbane, California, submitted a current report on August 12, 2026, covering two distinct disclosures. Under Item 2.02, the company furnished a press release titled "Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones" as Exhibit 99.1. According to the filing, this information is furnished and "shall not be deemed to be 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934."

Under Item 8.01 (Other Events), the company disclosed a second press release, attached as Exhibit 99.2, announcing that it is expanding the vonaprument Phase 3 program in geographic atrophy. The filing states the expansion includes adding a Month 24 dual primary endpoint to complement the Month 15 primary endpoint already in place, as well as launching an open-label extension study. Unlike Exhibit 99.1, the press release in Exhibit 99.2, other than the quotes contained within it, is incorporated by reference into the filing.

The filing also references "Key Anticipated Milestones" in the title of the Q2 press release, though the specific milestones are contained in the attached exhibit rather than in the body of the 8-K itself. Both press releases carry a date of August 12, 2026. The current report was signed by Jennifer Lew, Executive Vice President and Chief Financial Officer.

What Was Disclosed

Annexon's August 12, 2026 current report covered Q2 2026 financial results furnished as an exhibit and a Phase 3 program expansion for vonaprument in geographic atrophy, including a new Month 24 dual primary endpoint and an open-label extension study.